476 related articles for article (PubMed ID: 10561210)
1. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
2. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
[TBL] [Abstract][Full Text] [Related]
3. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB;
Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130
[TBL] [Abstract][Full Text] [Related]
6. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
7. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W;
Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
Bafaloukos D; Aravantinos G; Samonis G; Katsifis G; Bakoyiannis C; Skarlos D; Kosmidis P
Oncology; 1999 Apr; 56(3):198-201. PubMed ID: 10202274
[TBL] [Abstract][Full Text] [Related]
12. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Thigpen T; Brady MF; Homesley HD; Soper JT; Bell J
J Clin Oncol; 2001 Jan; 19(2):364-7. PubMed ID: 11208827
[TBL] [Abstract][Full Text] [Related]
14. Continued medical treatment for persistent early endometrial cancer in young women.
Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
16. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
17. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
18. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer.
Koyama H; Tominaga T; Asaishi K; Abe R; Iino Y; Enomoto K; Miura S; Nomura Y; Nakazato H; Abe O
Oncology; 1999; 56(4):283-90. PubMed ID: 10343191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
